Prodrugs: advantage or disadvantage?
Our knowledge of the peculiarities of prohormones is rather limited, both pharmacologically and clinically. Generalizations cannot be made except that the lapse of time until peak blood values of the active drug have been reached are always greater after intake of the prodrug than after intake of the drug. This finding is presumably of no clinical importance. If pharmacokinetic differences are limited to the phase of distribution, bioequivalence may be assumed. If, on the other hand, the area under the curve during the elimination phase is smaller for the prodrug than for the drug, the potency of the former should be decreased. A shift in the spectrum of endocrine actions as a result of the biotransformation of the prodrug into the active drug is rather the exception than the rule, and so is a change in side effects. If there are major differences in this respect, metabolic pathways in addition to those leading to the respective active drug must also be taken into consideration.
Hammerstein
J
J
Obstetrics and Gynecology Department, Klinikum Steglitz, Freie Universität Berlin, West Germany.
D001711:Biotransformation; D003278:Contraceptives, Oral, Hormonal / Q000493:pharmacokinetics*; D004967:Estrogens / Q000097:blood / Q000493:pharmacokinetics; D004997:Ethinyl Estradiol / Q000097:blood / Q000493:pharmacokinetics; D008234:Lynestrenol / Q000097:blood / Q000493:pharmacokinetics; D009640:Norethindrone / Q000097:blood / Q000493:pharmacokinetics; D011355:Prodrugs / Q000493:pharmacokinetics*; D011372:Progestins / Q000097:blood / Q000493:pharmacokinetics
D003278:Contraceptives, Oral, Hormonal; D004967:Estrogens; D011355:Prodrugs; D011372:Progestins; D004997:Ethinyl Estradiol; D008234:Lynestrenol; D009640:Norethindrone